Dr. Edgardo Santos' Interview with Jonathan Riess, MD, MS
Description
Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting
Dr. Edgardo Santos' Interview with Jonathan Riess, MD, MS
Dr. Riess highlighted that first-line osimertinib significantly prolongs progression-free survival in EGFR-mutant metastatic lung cancer, and the FLORA-2 study suggests adding chemotherapy may further improve overall survival, with circulating tumor DNA serving as a key marker for treatment intensification. Dr. Santos underscored the necessity of broad genetic profiling—including liquid biopsies—to personalize therapy based on high-risk factors like brain metastases and co-mutations, and anticipates next-generation EGFR inhibitors will further enhance outcomes.
United States
